Biotinidase Deficiency: Prevalence, Impact And Management Strategies
- PMID: 32440248
- PMCID: PMC7211084
- DOI: 10.2147/PHMT.S198656
Biotinidase Deficiency: Prevalence, Impact And Management Strategies
Abstract
Biotinidase deficiency is an autosomal recessive inherited neurocutaneous disorder. Clinically untreated patients with BD can present with variable neurological and dermatological signs, such as seizures, hypotonia, feeding problems, developmental delay, hearing loss, optic atrophy ataxia, alopecia, and skin rash. Clinical findings of patients with partial BD reported in the literature show that it can occur from infancy to adulthood. Outcomes of newborn screening programs support the fact that biotin treatment started after birth prevents patients with biotinidase deficiency from developing symptoms. Presence of late-onset cases with different clinical findings indicates that there is still much to learn about BD.
Keywords: biotin; biotinidase; newborn screening.
© 2020 Canda et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures
References
-
- Wolf B, Hsia YE, Sweetman L, et al. Multiple carboxylase deficiency: clinical and biochemical improvement following neonatal biotin treatment. Pediatrics. 1981;68(1):113–118. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
